Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in “The Lancet”6. November 2018|In Portfolio News|By eazee-designstudioThe recently completed Phase 2 clinical trial was designed to assess the safety, tolerability and immunogenicity of its lead vaccine candidate (MV-CHIK) to protect against Chikungunya fever, a mosquito-transmitted disease that has no current treatment or prevention options. The primary endpoint, defined as the presence of neutralizing antibodies against Chikungunya, four weeks after administration of one or two MV-CHIK injections, was met across all treatment groups. PrevNext
